The announcement details the initiation of a Phase III clinical trial for SYS6010, a drug developed by the company's subsidiary, in combination with another drug for advanced or metastatic NSCLC. The trial aims to evaluate the efficacy and safety of this combination therapy. The company notes that regulatory approval is still required for market launch and acknowledges the inherent risks in drug development.
Summary generated by AI · Always verify with source document
Stock Code: 300765
Stock Abbreviation: CSPC Pharmaceutical Group
Announcement No.: 2026-059
CSPC Pharmaceutical Group Limited
Announcement on the Initiation of Phase III Clinical Trial of SYS6010 by Controlling Subsidiary
The Company and all members of the Board of Directors guarantee the truthfulness, accuracy, and completeness of the information disclosed, and that there are no false records, misleading statements, or material omissions.
Sign in to read the full translation
Free accounts get 10 full releases per month. Pro subscribers get unlimited access.